obsidiantx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $325.04MM
Obsidian Therapeutics is a clinical-stage biotechnology specializing in engineered cell and gene therapies with a mission to deliver transformative outcomes for patients with intractable diseases. The company utilizes drug-responsive domains for controlled protein function in therapeutics, aiming for targeted treatment solutions. Obsidian Therapeutics was founded by Michael Gilman, Steve Shamah, and Tariq Kassum in 2015 and is headquartered in Cambridge, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/03/2024 | Series C | $160.5MM | $xx.xx | $507.38MM | Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Novo Holdings, Paradigm BioCapital, Ra Capital Management, Rtw Investments, Samsara, Surveyor Capital, Tcg Crossover Management, T. Rowe Price Associates, Wellington Management, Woodline Partners | |
Price per Share
$xx.xx
Shares Outstanding
84,567,145
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, Novo Holdings, Paradigm BioCapital, Ra Capital Management, Rtw Investments, Samsara, Surveyor Capital, Tcg Crossover Management, T. Rowe Price Associates, Wellington Management, Woodline Partners
|
||||||
09/09/2021 | Series B | $115.04MM | $xx.xx | $278.56MM | Amgen Ventures, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal Life Sciences, Ra Capital Management, Samsara, Soleus Capital, Surveyor Capital, Tcg Crossover Management, Vertex Pharmaceuticals, Vertex Ventures Hc | |
Price per Share
$xx.xx
Shares Outstanding
76,187,917
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal Life Sciences, Ra Capital Management, Samsara, Soleus Capital, Surveyor Capital, Tcg Crossover Management, Vertex Pharmaceuticals, Vertex Ventures Hc
|
||||||
12/06/2017 | Series A-2 | $12.03MM | $xx.xx | $116.85MM | Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc | |
Price per Share
$xx.xx
Shares Outstanding
12,025,212
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
|
||||||
12/06/2017 | Series A-1 | $30.2MM | $xx.xx | $116.85MM | Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc | |
Price per Share
$xx.xx
Shares Outstanding
26,747,257
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
|
||||||
12/06/2017 | Series A-3 | $7.27MM | $xx.xx | $116.85MM | Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc | |
Price per Share
$xx.xx
Shares Outstanding
4,948,612
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Amgen Ventures, Atlas Venture, Bristol Myers Squibb, Gv, Shangpharma Innovation, Takeda Ventures, Vertex Ventures Hc
|